Volume 4.32 | Aug 16

Mammary Cell News 4.32 August 16, 2012
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
FAM83A Confers EGFR-TKI Resistance in Breast Cancer Cells and in Mice
Breast cancers commonly become resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) however, the mechanisms of this resistance remain largely unknown. Researchers determined whether resistance may originate from molecular alterations that activate signaling downstream of EGFR. [J Clin Invest]
Full Article | Press Release

[FREE] ALDEFLUOR™ Protocol Optimization Kit – Get Yours
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

A Metabolic Pro-Survival Role for PML in Breast Cancer
Researchers identified a metabolic function for the promyelocytic leukemia (PML) gene, uncovering an unexpected role for this bona fide tumor suppressor in breast cancer cell survival. [J Clin Invest] Full Article

Dynamically Varying Interactions between Heregulin and ErbB Proteins Detected by Single-Molecule Analysis in Living Cells
Scientists observed the reaction kinetics between fluorescently labeled single heregulin molecules and ErbB3/B4 on the surfaces of MCF-7 human breast cancer cells. [Proc Natl Acad Sci USA] Abstract

The Hippo Pathway Target, YAP, Promotes Metastasis through Its TEAD-Interaction Domain
Researchers demonstrated that, in addition to increasing tumor growth, increased yes-associated protein (YAP) activity is potently prometastatic in breast cancer and melanoma cells. They also showed that, through its TEAD-interaction domain, YAP enhances multiple processes known to be important for tumor progression and metastasis. [Proc Natl Acad Sci USA] Abstract | Full Article

Gankyrin Promotes Breast Cancer Cell Metastasis by Regulating Rac1 Activity
Investigators found that knocking down Gankyrin expression in highly metastatic human breast cancer cells significantly decreases cancer cell migration and invasion. [Oncogene] Abstract

BCAR4 Induces Anti-Estrogen Resistance but Sensitizes Breast Cancer to Lapatinib
Researchers determined whether BCAR4 expression sensitizes breast cancer cells to lapatinib and identified a subgroup of patients who may benefit from ERBB2-targeted therapies despite having tumors with low ERBB2 expression. [Br J Cancer] Abstract

Induction of Endoplasmic Reticulum Stress Response by the Indole-3-Carbinol Cyclic Tetrameric Derivative CTet in Human Breast Cancer Cell Lines
Researchers have previously shown that the indole-3-carbinol cyclic tetrameric derivative CTet induces autophagy and inhibits cell proliferation via inhibition of Akt activity and overexpression of p21/CDKN1A and GADD45A, in both estrogen receptor-positive and triple negative breast cancer cell lines. Here, they further characterized the autophagic response and investigated the mechanism through which CTet regulates these events. [PLoS One] Full Article

Role of KCNMA1 in Breast Cancer
Findings revealed that enhanced expression of KCNMA1 correlates with and contributes to high proliferation rate and malignancy of breast cancer. [PLoS One] Full Article

Interferon Regulatory Factor 4 Binding Protein Is a Novel p53 Target Gene and Suppresses Cisplatin-Induced Apoptosis of Breast Cancer Cells
Results demonstrated that interferon regulatory factor 4 binding protein (IBP) is a novel p53 target gene that suppresses cisplatin-mediated apoptosis of breast cancer cells via negative feedback regulation of the p53 signaling pathway, suggesting that IBP may serve as a target for pharmacologic intervention of breast cancer resistant to cisplatin therapy. [Mol Cancer] Abstract | Full Article

CLINICAL RESEARCH

Subcutaneous versus Intravenous Administration of (Neo)Adjuvant Trastuzumab in Patients with HER2-Positive, Clinical Stage I-III Breast Cancer: A Phase III, Open-Label, Multicentre, Randomized Trial
Scientists compared the pharmacokinetic profile, efficacy, and safety of subcutaneous and intravenous formulations in patients with HER2-positive early breast cancer. [Lancet Oncol] Abstract

Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid
Investigators found that denosumab was superior to zoledronic acid in reducing bone-related complications of metastatic breast cancer and maintained health-related quality of life, providing an efficacious, well-tolerated treatment option for patients with bone metastases from breast cancer. [Clin Cancer Res]
Abstract | Press Release

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells

INDUSTRY NEWS

Canadian Breast Cancer Foundation Funds Over $3.2 Million in Earlier Detection Research
Eight innovative new projects aimed at earlier detection of breast cancer have received over $3.2 million in funding from the Canadian Breast Cancer Foundation. [Canadian Breast Cancer Foundation] Press Release

Licensing of CTx FAK Inhibitor Programs Bringing Treatment Hope for Triple-Negative Breast Cancer
Cancer Research Technology is entering into two licences with Cancer Therapeutics CRC (CTx) to commercialize CTx’s pre-clinical focal adhesion kinase (FAK) inhibitor programs. [Cancer Therapeutics CRC] Press Release

Epic Sciences Announces Six Pharma Circulating Tumor Cell Collaborations
Epic Sciences, Inc. announced that it has established collaborations with six pharmaceutical partners employing Epic’s proprietary Circulating Tumor Cell (CTC) technology. The collaborations include 12 clinical trials involving over 40 distinct projects measuring 18 different protein or genomic tumor markers on CTCs. The clinical trials include over 1500 patients and 2500 clinical samples in prostate, lung, breast, pancreatic and ovarian cancers. [Epic Sciences, Inc.] Press Release

Rubicon’s NovaPLEX™ Sample Preparation Technologies Are Helping to Achieve Breakthroughs in Molecular Diagnostics and Cancer Research
Rubicon Genomics, Inc. reported that its NovaPLEX™ family of sample preparation technologies is increasing the feasibility and utility of molecular diagnostic testing and helping to address the shortage of patient samples that is hampering new drug discovery and the development of personalized medicine. These sample preparation technologies are already being used in breast cancer. [Rubicon Genomics, Inc.]
Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW American Association for Cancer Research (AACR): Tumor Invasion and Metastasis
January 20-23, 2013
San Diego, United States

Visit
our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)


Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)


Postdoctoral Position – Breast Cancer (Albert Einstein College of Medicine)

Posdoctoral Position – Androgen Dependent Breast Cancer (The Institute of Cancer Research)

Posdoctoral Position(s) – Receptor Trafficking in Mammary Carcinogenesis (The Beatson Institute for Cancer Research)

Principal Investigator(s) – Cancer Research (National University of Singapore)


Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us